The latest price target for Enanta Pharma (NASDAQ:ENTA) was reported by HC Wainwright & Co. on October 10, 2024. The analyst firm set a price target for $27.00 expecting ENTA to rise to within 12 months (a possible 189.08% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Enanta Pharma (NASDAQ:ENTA) was provided by HC Wainwright & Co., and Enanta Pharma reiterated their buy rating.

The last upgrade for Enanta Pharmaceuticals Inc happened on July 6, 2022 when Evercore ISI Group raised their price target to $62. Evercore ISI Group previously had an in-line for Enanta Pharmaceuticals Inc.

The last downgrade for Enanta Pharmaceuticals Inc happened on August 8, 2023 when Jefferies changed their price target from $49 to $18 for Enanta Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enanta Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enanta Pharma was filed on October 10, 2024 so you should expect the next rating to be made available sometime around October 10, 2025.

While ratings are subjective and will change, the latest Enanta Pharma (ENTA) rating was a reiterated with a price target of $27.00 to $27.00. The current price Enanta Pharma (ENTA) is trading at is $9.34, which is out of the analyst’s predicted range.